OmniAb, Inc. (OABI) Stock Price & How to Invest
Last updated November 2026
Short answer
OmniAb (Nasdaq: OABI) is a royalty and milestone business, not a drug developer: it licenses antibody discovery technology to roughly 110 pharma and biotech partners and gets paid access fees, service revenue, milestones and single-digit royalties as those partners' programs advance. Anyone buying the shares is buying a claim on ~425 partner programs they do not control, funded by a ~$52M cash pile against a still-unprofitable income statement. After a ~143% rise in 2026, the shares closed at ~$4.57 on October 16, 2026 for a market value near ~$665M.
OABI stock price
As of 2026-11-16, OmniAb, Inc. (OABI) last closed at $4.89, up 221.7% over the past year. Over the past 52 weeks it has traded between $1.36 and $5.30.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or OmniAb, Inc.'s investor relations page. Walnut is informational, not investment advice.
OABI key stats
At $4.89 on November 16, 2026, OmniAb, Inc. (OABI) has a market cap of $713M.
- Market cap
- $713M
- Price to book
- 2.9
- Beta
- 1.36
Market cap, P/E and yield are measured at the $4.89 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with OmniAb, Inc. (OABI)?
The last two weeks for OmniAb, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- OABI closed at $4.89 on November 16, 2026, down 7.7% over the past five trading days (from $5.30).
OmniAb, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
OmniAb, Inc. (OABI) latest quarter
OmniAb reported revenue of $4.0 million for Q3 2026, up 78% from a year earlier (OmniAb, Oct 30, 2026).
Source: OmniAb Q3 2026 results, Oct 30, 2026. Full earnings breakdown
What does OmniAb, Inc. (OABI) do?
OmniAb was spun out of Ligand Pharmaceuticals in November 2022 and sells access to antibody discovery technology rather than drugs. Its platform centres on transgenic animals engineered to produce human-sequence antibodies (OmniRat, OmniMouse, OmniChicken, OmniTaur, OmniClic) plus the xPloration high-throughput single-cell screening system and an ion channel screening group acquired with Icagen. Partners license the platforms, run their own discovery campaigns, and owe OmniAb payments at defined points: an upfront or annual access fee, service and instrument revenue, clinical and regulatory milestones, and a royalty on eventual product sales. As of Q2 2026 there were ~110 active partners, ~425 active programs, ~34 of those in clinical development or already approved, eight of the ten largest pharma companies among the partner base, and roughly 98% of programs carrying contracted future economics. Management has cited more than ~$3B of total contracted milestone potential at an average royalty near ~3.4%.
The investment picture is unusually lumpy, because the revenue arrives when somebody else's molecule moves. Q2 2026 revenue was ~$13.4M against ~$3.9M a year earlier, almost entirely on license and milestone payments as programs such as Johnson & Johnson's ramantamig and Merck KGaA's precemtabart tocenteban jumped from Phase 1 into Phase 3. Net loss narrowed to ~$5.9M from ~$15.9M, and first-half operating cash burn fell to ~$2.2M from ~$21.0M. Set against that, trailing twelve-month revenue is only ~$38M on a market value that was ~$491M in August 2026 and ~$665M by mid-October 2026 (roughly ~17x sales), the trailing net loss is ~$44M once amortisation of acquired intangibles is counted, and royalty revenue itself was just ~$0.3M in the quarter. On 17 August 2026 the company added a global collaboration and license agreement with Eli Lilly for an ion channel program and lifted year-end cash guidance to ~$49M to ~$53M from ~$37M to ~$41M, while leaving the 2026 revenue range at ~$32M to ~$36M. The shares jumped ~18% on that announcement. At an October 6, 2026 Investor & Analyst Day the company introduced OmniTides, a peptide discovery offering built on its OmniUltra transgenic chicken platform, opened the xPloration screening system to purchase by all customers from October 2026 (guiding to ~$2M to ~$3M of xPloration revenue in 2026, doubling in 2027 and again in 2028), and said partner disclosures point to potential primary completion of up to 19 clinical trials across the rest of 2026 and 2027. At ~$4.57 on October 16, 2026 the stock was up ~143% year to date and ~169% over one year, near the top of a ~$1.30 to ~$5.43 52-week range. Third-quarter results are due October 30, 2026, with consensus at ~$3.5M of revenue and a ~$0.13 per-share loss, a reminder of how front-loaded 2026 milestones were.
What's driving OmniAb, Inc. (OABI)?
1. Clinical graduation across ~34 partner programs
The economics compound only as partner molecules move through phases, and 2026 delivered several jumps at once, including two programs advancing from Phase 1 to Phase 3 and four new clinical entrants through mid-year. Each stage transition triggers a contracted milestone, and each approval converts a program from milestone payer into royalty payer. Because ~98% of active programs carry contracted future economics, the pipeline count is a reasonable proxy for the size of the eventual claim.
2. Milestone revenue reaching operating breakeven
Costs came down while revenue tripled: first-half R&D fell ~18% and G&A ~15% year over year, and operating cash use dropped to ~$2.2M for the half. Guidance frames 2026 GAAP operating expenses at ~$84M to ~$88M with cash expenses of ~$51M to ~$55M against ~$32M to ~$36M of revenue, so the gap is narrowing without new equity. No shares were issued under the ~$100M ATM in the first half, leaving ~$88.3M of that authorisation unused.
3. Business development that is paid up front
The August 2026 Lilly ion channel agreement carries an upfront payment plus eligibility for tiered royalties on global net sales, and it is what allowed the year-end cash outlook to rise by roughly ~$12M at the midpoint without touching the revenue range. Deals of this shape matter twice: they fund the platform today and add another royalty-bearing shot on goal later. Ion channel work also puts the Icagen assets back to use after a ~$2.9M intangible impairment in Q1 2026 tied to discontinued ion channel programs. The October 2026 Investor Day widened the product set again with OmniTides for peptide discovery and open commercial sales of xPloration instruments and consumables, which management sizes as a market of more than $500M.
4. Royalties as the long-dated part of the story
Royalty revenue was ~$0.3M in Q2 2026 and ~$0.5M in the first half, so essentially none of the current valuation rests on realised royalties. The stated average rate of ~3.4% on partner net sales means the line only becomes material if several partner products reach commercial scale. Timing sits entirely with the partners, and a single large approval would change the revenue mix far more than any internal decision at OmniAb.
What are the risks to OmniAb, Inc. (OABI)?
Revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate. OmniAb controls none of the programs that pay it, so a partner deprioritising a molecule, a failed trial, or a slipped filing removes a milestone with no offsetting action available. The company remains unprofitable on a trailing basis (~$44M net loss) with a large non-cash amortisation charge on acquired intangibles, and Q1 2026 included a ~$2.9M impairment of a customer relationship intangible after ion channel programs were discontinued. Dilution mechanics are real even without an equity raise: ~145.4M shares outstanding sit alongside ~14.99M price-vesting earnout shares, ~18.6M warrants expiring 1 November 2027, and ~$88.3M of unused ATM capacity. Liquidity itself is not flagged as a concern (the 10-Q states cash is sufficient for at least twelve months and no going-concern warning is disclosed, no material pending legal proceedings are reported, and the shares remain listed on Nasdaq with no delisting determination), but the stock has traded between ~$1.30 and ~$5.43 over the past year, rose ~37% on the Q2 print and ~18% on the Lilly deal, and was up ~119% over the three months to October 16, 2026, so the market value moves far more than the underlying contracts do. After that run, valuation is now a risk in its own right: at ~17x trailing sales the shares price in milestone and royalty growth that consensus does not yet show, with Q3 2026 revenue expected near only ~$3.5M.
What is the OmniAb, Inc. (OABI) forecast?
6 analysts publish price targets on OABI, averaging $8.33 as of November 2026, or +70.3% against the $4.89 share price on November 16, 2026. The published targets run from $5.00 to $12.00, a wide spread, and the ratings split 7 buy, 0 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full OABI forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is OABI a buy or a sell?
We give no verdict on OmniAb, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Clinical graduation across ~34 partner programs. The economics compound only as partner molecules move through phases, and 2026 delivered several jumps at once, including two programs advancing from Phase 1 to Phase 3 and four new clinical entrants through mid-year. The most optimistic published target, $12.00, assumes this works close to its best case.
The case against. Revenue is lumpy by construction: management has said milestone revenue can vary materially between quarters and that 2026 activity is front-loaded, so a strong Q2 is not a run rate. The most pessimistic target, $5.00, is roughly what OABI is worth if this bites instead.
Read the full bull and bear case on OABI, including what would have to change to break either one. Walnut is not an investment adviser.
Has OmniAb, Inc. (OABI) split its stock?
No. OmniAb, Inc. (OABI) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is OmniAb, Inc. (OABI) valued?
Market cap, P/E and dividend yield at today's price are in the OABI key stats above. The business figures below come from OmniAb, Inc.'s reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$38M
- Q2 2026 revenue: ~$13.4M, up from ~$3.9M a year earlier; EPS ~-$0.05 vs ~-$0.13 consensus
- 2026 revenue guidance: ~$32M to ~$36M (as of August 2026)
- Net loss: ~$5.9M in Q2 2026, ~$44M trailing twelve months
- Margins: Gross margin ~98%, operating margin ~-49% (trailing)
- Cash and debt: ~$52M cash and short-term investments at 30 June 2026, ~$19M debt; year-end cash guidance ~$49M to ~$53M
- Next report: October 30, 2026; consensus ~$3.5M revenue, ~-$0.13 EPS
As of October 2026: A ~17x multiple on ~$38M of trailing revenue is a platform multiple, not a biotech-pipeline multiple, and after the 2026 run it leans heavily on contracted future economics rather than current profit. Two figures pull against each other: the milestone line tripled year over year while the royalty line was ~$0.3M for the quarter, and consensus for the September quarter is only ~$3.5M of revenue. Cash of ~$52M and first-half operating burn of ~$2.2M mean the balance sheet is not the pressing question at these levels; the timing of partner programs, including the up to 19 trial completions management flagged through 2027, is.
Who competes with OmniAb, Inc. (OABI)?
Transgenic-animal antibody discovery platforms
Ablexis (AlivaMab Mouse) and its services arm, Crescendo Biologics, Harbour Antibodies, Alloy Therapeutics, RenBio and Ligand Pharmaceuticals license comparable engineered-animal systems. OmniAb's 10-K names this group directly. Competition here is over which animal system produces developable human-sequence antibodies fastest, and increasingly over which platforms handle hard targets such as multi-pass membrane proteins.
Discovery businesses paid in downstream economics
Adimab, WuXi Biologics and Charles River (which absorbed Distributed Bio) run the same commercial model of front-end discovery plus milestones and royalties, and AbCellera pursues a technology-plus-royalty structure with a far larger balance sheet. All are bidding for the same pharma partnerships, and the negotiating variable is usually royalty rate and milestone schedule rather than the science.
In-house pharma discovery and AI-designed antibodies
The most persistent alternative is a large partner deciding it does not need an outside platform. Regeneron's VelocImmune is the clearest example of a fully internalised transgenic capability, and computational and generative protein-design approaches are being positioned as substitutes for animal-based immunisation. Both routes reduce the number of programs that ever carry an OmniAb royalty.
What stocks are similar to OmniAb, Inc. (OABI)?
Other names that sit close to OABI: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in OmniAb, Inc. (OABI)
There are three common ways to get OABI exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so OABI sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where OABI fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on OmniAb, Inc. (OABI)
OABI is an indirect bet on other companies' clinical timetables, where Q2 2026 finally showed the milestone economics working and the loss shrinking, but the royalty line is still measured in hundreds of thousands of dollars while the stock now prices in far more, at ~17x trailing sales after more than doubling in 2026.
More on OmniAb, Inc. (OABI)
Whether OABI is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OABI a buy or a sell?, and where the stock could go from here in the OABI stock forecast.
For income investors, whether OABI pays a dividend and how the payout looks is covered in does OABI pay a dividend? And to weigh OABI against a peer, read the full side-by-side comparisons: OABI vs REGN and OABI vs HNGE.
Wondering how OABI fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about OmniAb, Inc.
Ask Walnut's AI anything about OABI and see how it fits what you own.
FAQ
What does OmniAb actually sell?
+
Access to antibody discovery technology, not medicines. Partners license platforms such as OmniRat, OmniMouse, OmniChicken and OmniTaur, or purchase xPloration screening instruments and ion channel services, then run their own programs. OmniAb collects access fees, service revenue, milestones as programs advance, and royalties on any product that reaches the market.
Is OmniAb profitable?
+
Not yet. Q2 2026 net loss was ~$5.9M, improved from ~$15.9M a year earlier, and the trailing twelve-month loss is around ~$44M. A large slice of that is non-cash amortisation of intangibles acquired before and during the Ligand spin-off, which is why first-half operating cash use was only ~$2.2M against a much larger reported loss.
Why did the revenue triple in Q2 2026?
+
License and milestone revenue accounted for ~$9.5M of the ~$13.4M quarter, driven by partner programs hitting contracted stages. Johnson & Johnson's ramantamig and Merck KGaA's precemtabart tocenteban both moved from Phase 1 to Phase 3. Management has said milestone revenue varies materially quarter to quarter and that 2026 activity is front-loaded, so the quarter is not a run rate.
How big can the royalty stream get?
+
Management has pointed to more than ~$3B of total contracted milestone potential across the portfolio at an average royalty near ~3.4% of partner net sales. Realised royalties today are small (~$0.3M in Q2 2026, ~$0.5M in the first half), so the size of the eventual stream depends on how many of the ~34 clinical or approved programs reach commercial scale and when.
What was the Eli Lilly agreement announced in August 2026?
+
A global collaboration and license agreement covering an ion channel program, using OmniAb's ion channel discovery and screening capability. OmniAb receives an upfront payment and is eligible for tiered royalties on global net sales. Alongside other recent licensing activity it lifted year-end 2026 cash guidance to ~$49M to ~$53M from ~$37M to ~$41M, roughly ~$12M higher at the midpoint.
How much cash does OmniAb have, and is dilution a concern?
+
Cash and equivalents were ~$24.3M with ~$27.7M in short-term investments at 30 June 2026, so ~$52M in total with no reported debt, and the 10-Q states this funds operations for at least twelve months. Potential supply above the ~145.4M shares outstanding includes ~14.99M price-vesting earnout shares, ~18.6M warrants expiring 1 November 2027, and ~$88.3M still available under a ~$100M ATM that was untouched in the first half.
How would someone hold OABI in a thematic basket?
+
OABI is a platform-royalty exposure rather than a clinical-asset exposure, so it tends to be grouped with drug-discovery tooling and royalty models (AbCellera, Ligand, Royalty Pharma) rather than with therapeutics developers. Position sizing usually reflects the volatility: the shares ranged from ~$1.30 to ~$5.43 over the past year, moved ~37% on a single earnings release and more than doubled in 2026. In Walnut you can add it to a basket with a stated thesis and a target weight, then place the order through your connected broker.
Why has OABI stock risen so much in 2026?
+
Three events stacked up. The Q2 2026 report showed revenue more than tripling to ~$13.4M on partner milestones and a much smaller loss, and the shares rose ~37% on it; the August 17 Eli Lilly ion channel agreement lifted year-end cash guidance and the stock rose ~18%; and the October 6 Investor Day introduced OmniTides and opened xPloration sales. By October 16, 2026 the shares were at ~$4.57, up ~143% year to date and ~169% over a year. Walnut is not an investment adviser, and past moves do not predict future ones.
What is OmniTides?
+
OmniTides is a peptide discovery offering OmniAb introduced at its October 6, 2026 Investor & Analyst Day. It uses the OmniUltra transgenic chicken platform and runs as an integrated discovery-to-synthesis workflow, with peptide manufacturing handled by qualified contract research organizations. It extends the company beyond antibodies into peptides, another route to licensing fees, milestones and royalties.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with OmniAb, Inc.'s investor relations page or your broker before making investment decisions.